Literature DB >> 34254206

Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.

Rhubaniya Mahendran1, Soo Kun Lim2, Kien Chai Ong1, Kek Heng Chua1, Hwa Chia Chai3.   

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic kidney disorder that impairs renal functions progressively leading to kidney failure. The disease affects between 1:400 and 1:1000 ratio of the people worldwide. It is caused by the mutated PKD1 and PKD2 genes which encode for the defective polycystins. Polycystins mimic the receptor protein or protein channel and mediate aberrant cell signaling that causes cystic development in the renal parenchyma. The cystic development is driven by the increased cyclic AMP stimulating fluid secretion and infinite cell growth. In recent years, natural product-derived small molecules or drugs targeting specific signaling pathways have caught attention in the drug discovery discipline. The advantages of natural products over synthetic drugs enthusiast researchers to utilize the medicinal benefits in various diseases including ADPKD.
CONCLUSION: Overall, this review discusses some of the previously studied and reported natural products and their mechanisms of action which may potentially be redirected into ADPKD.
© 2021. Japanese Society of Nephrology.

Entities:  

Keywords:  ADPKD; Cell proliferation; Fluid secretion; cAMP

Mesh:

Substances:

Year:  2021        PMID: 34254206     DOI: 10.1007/s10157-021-02111-x

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  65 in total

Review 1.  Transepithelial chloride secretion and cystogenesis in autosomal dominant polycystic kidney disease.

Authors:  A Persu; O Devuyst
Journal:  Nephrol Dial Transplant       Date:  2000-06       Impact factor: 5.992

Review 2.  Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hannah A Blair; Gillian M Keating
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

3.  Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion.

Authors:  Carolina Cannillo Graffe; Jesper Nørgaard Bech; Thomas Guldager Lauridsen; Erling Bjerregaard Pedersen
Journal:  Am J Physiol Renal Physiol       Date:  2012-01-18

Review 4.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

5.  Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?

Authors:  Reem A Mustafa; Alan S L Yu
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-13       Impact factor: 8.237

6.  Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model.

Authors:  Yangyang Zhu; Tian Teng; Hu Wang; Hao Guo; Lei Du; Baoxue Yang; Xiaoxing Yin; Ying Sun
Journal:  Food Funct       Date:  2018-01-24       Impact factor: 5.396

Review 7.  Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

Authors:  Jared J Grantham; Arlene B Chapman; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2005-10-19       Impact factor: 8.237

Review 8.  Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.

Authors:  Fouad T Chebib; Vicente E Torres
Journal:  Am J Kidney Dis       Date:  2015-10-31       Impact factor: 8.860

Review 9.  Direct activation of ENaC by angiotensin II: recent advances and new insights.

Authors:  Oleg Zaika; Mykola Mamenko; Alexander Staruschenko; Oleh Pochynyuk
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

10.  Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.

Authors:  Yani Liu; Xiaomei Luo; Chunxiao Yang; Tingyu Yang; Jiali Zhou; Shaojun Shi
Journal:  Mol Med Rep       Date:  2016-08-09       Impact factor: 2.952

View more
  1 in total

1.  Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Shunichiro Tsukamoto; Shingo Urate; Takayuki Yamada; Kengo Azushima; Takahiro Yamaji; Sho Kinguchi; Kazushi Uneda; Tomohiko Kanaoka; Hiromichi Wakui; Kouichi Tamura
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.